Neogenomics (NEO) Capital Expenditures (2010 - 2026)

Neogenomics has reported Capital Expenditures for 17 years, with the latest figure at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 11.11% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 3132.88% YoY), and the FY2025 full-year result was $1.7 million, up 69.37% from the prior year.
• Capital Expenditures for Q1 2026 stood at $5.0 million, up from -$17.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $16.2 million in Q2 2023, with the low at -$28.4 million in Q4 2024.
• Historically, Capital Expenditures has averaged $589647.1 across 5 years, with a median of $5.6 million in 2024.
• The largest YoY upside for Capital Expenditures was 375.72% in 2024 against a maximum downside of 109323.08% in 2024.
• Neogenomics' Capital Expenditures stood at -$24.7 million in 2022, then surged by 99.89% to -$26000.0 in 2023, then plunged by 109323.08% to -$28.4 million in 2024, then jumped by 38.76% to -$17.4 million in 2025, then jumped by 128.7% to $5.0 million in 2026.
• The last three Capital Expenditures figures came in at $5.0 million (Q1 2026), -$17.4 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.